# Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

> **NCT05694312** · PHASE2 · RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 45 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Monoclonal B-Cell Lymphocytosis CLL-Type

## Interventions

- **DRUG:** Ibrutinib 420 mg

## Key facts

- **NCT ID:** NCT05694312
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-24
- **Primary completion:** 2025-05
- **Final completion:** 2026-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694312, "Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05694312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*